Microsatellite polymorphism in the heme oxygenase-1 promoter is associated with nonsevere and late-onset preeclampsia

Hypertension

Volumn 64, Issue 1, 2014, Pages 172-177

  Kaartokallio, Tea ^a   Klemetti, Miira M ^a,c,d   Timonen, Anni ^a,b   Uotila, Jukka ^e   Heinonen, Seppo ^f   Kajantie, Eero ^g,h,i   Kere, Juha ^a,j,k   Kivinen, Katja ^l   Pouta, Anneli ^g,i   Lakkisto, Päivi ^b,c,m   Laivuori, Hannele ^a,b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d SOUTH KARELIA CENTRAL HOSPITAL   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

^g NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^h UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

ⁱ OULU UNIVERSITY HOSPITAL   (Finland)

^j SCIENCE FOR LIFE LABORATORY   (Sweden)

^k FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^l WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^m MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

more..

Author keywords

heme oxygenase 1; preeclampsia; vascular diseases

Indexed keywords

DNA FRAGMENT; HEME OXYGENASE 1; REPETITIVE DNA;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MULTIPARA; PATHOGENESIS; PREECLAMPSIA; PRIMIPARA; PRIORITY JOURNAL; PROMOTER REGION; SMALL FOR DATE INFANT;

HEME OXYGENASE-1; PREECLAMPSIA; VASCULAR DISEASES;

ADULT; ALLELES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEME OXYGENASE-1; HUMANS; MICROSATELLITE REPEATS; POLYMORPHISM, GENETIC; PRE-ECLAMPSIA; PREGNANCY; PROMOTER REGIONS, GENETIC; SEVERITY OF ILLNESS INDEX;

EID: 84902544585     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03337     Document Type: Article

References (49)

1. World Health Organization. World Health Report 2005: Make Every Mother and Child Count. Geneva, Switzerland: World Health Organization; 2005.
2. Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor RN, Powers RW, Charnock-Jones DS, Redman CW. Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013;61: 932-942.
3. George EM, Granger JP. Recent insights into the pathophysiology of preeclampsia. Expert Rev Obstet Gynecol. 2010;5: 557-566.
4. Sibai BM, Ewell M, Levine RJ, Klebanoff MA, Esterlitz J, Catalano PM, Goldenberg RL, Joffe G. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol. 1997;177: 1003-1010.
5. Mostello D, Catlin TK, Roman L, Holcomb WL Jr, Leet T. Preeclampsia in the parous woman: who is at risk? Am J Obstet Gynecol. 2002;187: 425-429.
6. Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem. 1969;244: 6388-6394.
7. Maines MD, Kappas A. Cobalt induction of hepatic heme oxygenase; with evidence that cytochrome P-450 is not essential for this enzyme activity. Proc Natl Acad Sci U S A. 1974;71: 4293-4297.
8. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev. 2008;60: 79-127.
9. Levytska K, Kingdom J, Baczyk D, Drewlo S. Heme oxygenase-1 in placental development and pathology. Placenta. 2013;34: 291-298.
10. Li M, Kim DH, Tsenovoy PL, Peterson SJ, Rezzani R, Rodella LF, Aronow WS, Ikehara S, Abraham NG. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes. 2008;57: 1526-1535.
11. Chen YH, Lin SJ, Lin MW, Tsai HL, Kuo SS, Chen JW, Charng MJ, Wu TC, Chen LC, Ding YA, Pan WH, Jou YS, Chau LY. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet. 2002;111: 1-8.
12. Ono K, Goto Y, Takagi S, Baba S, Tago N, Nonogi H, Iwai N. A promoter variant of the heme oxygenase-1 gene may reduce the incidence of ischemic heart disease in Japanese. Atherosclerosis. 2004;173: 315-319.
13. Lakkisto P, Siren JM, Kytö V, Forsten H, Laine M, Pulkki K, Tikkanen I. Heme oxygenase-1 induction protects the heart and modulates cellular and extracellular remodelling after myocardial infarction in rats. Exp Biol Med (Maywood). 2011;236: 1437-1448.
14. Bao W, Song F, Li X, Rong S, Yang W, Wang D, Xu J, Fu J, Zhao Y, Liu L. Association between heme oxygenase-1 gene promoter polymorphisms and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol. 2010;172: 631-636.
15. Qiu C, Hevner K, Enquobahrie DA, Williams MA. Maternal serum hemeoxygenase- 1 (HO-1) concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. PLoS One. 2012;7:e48060.
16. Denschlag D, Marculescu R, Unfried G, Hefler LA, Exner M, Hashemi A, Riener EK, Keck C, Tempfer CB, Wagner O. The size of a microsatellite polymorphism of the haem oxygenase 1 gene is associated with idiopathic recurrent miscarriage. Mol Hum Reprod. 2004;10: 211-214.
17. Ahmed A, Rahman M, Zhang X, Acevedo CH, Nijjar S, Rushton I, Bussolati B, St John J. Induction of placental heme oxygenase-1 is protective against TNFalpha-induced cytotoxicity and promotes vessel relaxation. Mol Med. 2000;6: 391-409.
18. Farina A, Sekizawa A, De Sanctis P, Purwosunu Y, Okai T, Cha DH, Kang JH, Vicenzi C, Tempesta A, Wibowo N, Valvassori L, Rizzo N. Gene expression in chorionic villous samples at 11 weeks' gestation from women destined to develop preeclampsia. Prenat Diagn. 2008;28: 956-961.
19. McLaughlin BE, Lash GE, Smith GN, Marks GS, Nakatsu K, Graham CH, Brien JF. Heme oxygenase expression in selected regions of term human placenta. Exp Biol Med (Maywood). 2003;228: 564-567.
20. Kreiser D, Baum M, Seidman DS, Fanaroff A, Shah D, Hendler I, Stevenson DK, Schiff E, Druzin ML. End tidal carbon monoxide levels are lower in women with gestational hypertension and pre-eclampsia. J Perinatol. 2004;24: 213-217.
21. Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, Devey LR, Wigmore SJ, Abbas A, Hewett PW, Ahmed A. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation. 2007;115: 1789-1797.
22. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350: 672-683.
23. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355: 992-1005.
24. Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, Shibahara S, Sasaki H. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet. 2000;66: 187-195.
25. ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol. 2002;99: 159-167.
26. Saukkonen K, Lakkisto P, Kaunisto MA, Varpula M, Voipio-Pulkki LM, Varpula T, Pettilä V, Pulkki K. Heme oxygenase 1 polymorphisms and plasma concentrations in critically ill patients. Shock. 2010;34: 558-564.
27. Raymond M, Rousset F. GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism. J Heredity. 1995;86: 248-249.
28. Rousset F. genepop'007: a complete re-implementation of the genepop software for Windows and Linux. Mol Ecol Resour. 2008;8: 103-106.
29. Lachmeijer AM, Arngrímsson R, Bastiaans EJ, Frigge ML, Pals G, Sigurdardóttir S, Stéfansson H, Pálsson B, Nicolae D, Kong A, Aarnoudse JG, Gulcher JR, Dekker GA, ten Kate LP, Stéfansson K. A genome-wide scan for preeclampsia in the Netherlands. Eur J Hum Genet. 2001;9: 758-764.
30. Wu L, Wang R. Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev. 2005;57: 585-630.
31. Zhao H, Wong RJ, Kalish FS, Nayak NR, Stevenson DK. Effect of heme oxygenase- 1 deficiency on placental development. Placenta. 2009;30: 861-868.
32. Zenclussen ML, Casalis PA, El-Mousleh T, Rebelo S, Langwisch S, Linzke N, Volk HD, Fest S, Soares MP, Zenclussen AC. Haem oxygenase- 1 dictates intrauterine fetal survival in mice via carbon monoxide. J Pathol. 2011;225: 293-304.
33. Zhao H, Azuma J, Kalish F, Wong RJ, Stevenson DK. Maternal heme oxygenase 1 regulates placental vasculature development via angiogenic factors in mice. Biol Reprod. 2011;85: 1005-1012.
34. George EM, Hosick PA, Stec DE, Granger JP. Heme oxygenase inhibition increases blood pressure in pregnant rats. Am J Hypertens. 2013;26: 924-930.
35. George EM, Arany M, Cockrell K, Storm MV, Stec DE, Granger JP. Induction of heme oxygenase-1 attenuates sFlt-1-induced hypertension in pregnant rats. Am J Physiol Regul Integr Comp Physiol. 2011;301:R1495-R1500.
36. Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb Res. 2011;127(suppl 3):S72-S75.
37. Oudejans CB, van Dijk M, Oosterkamp M, Lachmeijer A, Blankenstein MA. Genetics of preeclampsia: paradigm shifts. Hum Genet. 2007;120: 607-612.
38. Laivuori H, Tikkanen MJ, Ylikorkala O. Hyperinsulinemia 17 years after preeclamptic first pregnancy. J Clin Endocrinol Metab. 1996;81: 2908-2911.
39. Hubel CA, Snaedal S, Ness RB, Weissfeld LA, Geirsson RT, Roberts JM, Arngrímsson R. Dyslipoproteinaemia in postmenopausal women with a history of eclampsia. BJOG. 2000;107: 776-784.
40. Lampinen KH, Rönnback M, Kaaja RJ, Groop PH. Impaired vascular dilatation in women with a history of pre-eclampsia. J Hypertens. 2006;24: 751-756.
41. Haukkamaa L, Salminen M, Laivuori H, Leinonen H, Hiilesmaa V, Kaaja R. Risk for subsequent coronary artery disease after preeclampsia. Am J Cardiol. 2004;93: 805-808.
42. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.
43. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009;53: 944-951.
44. Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, Toma T, Ohta K, Kasahara Y, Koizumi S. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest. 1999;103: 129-135.
45. Sidle EH, Casselman R, Smith GN. Effect of cigarette smoke on placental antioxidant enzyme expression. Am J Physiol Regul Integr Comp Physiol. 2007;293:R754-R758. (Pubitemid 47205060)
46. Mehendale R, Hibbard J, Fazleabas A, Leach R. Placental angiogenesis markers sFlt-1 and PlGF: response to cigarette smoke. Am J Obstet Gynecol. 2007;197:363.e1-363.e5.
47. El-Mousleh T, Casalis PA, Wollenberg I, Zenclussen ML, Volk HD, Langwisch S, Jensen F, Zenclussen AC. Exploring the potential of low doses carbon monoxide as therapy in pregnancy complications. Med Gas Res. 2012;2:4.
48. Conde-Agudelo A, Althabe F, Belizán JM, Kafury-Goeta AC. Cigarette smoking during pregnancy and risk of preeclampsia: a systematic review. Am J Obstet Gynecol. 1999;181: 1026-1035.
49. Ryter SW, Choi AM. Heme oxygenase-1/carbon monoxide: from metabolism to molecular therapy. Am J Respir Cell Mol Biol. 2009;41: 251-260.